HomeAKBLF • OTCMKTS
add
ALK-Abello A/S
Previous close
$25.31
Year range
$19.90 - $27.03
Market cap
33.20B DKK
Avg Volume
69.00
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
In the news
Financials
Income Statement
Revenue
Net income
| (DKK) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 1.52B | 12.66% |
Operating expense | 547.00M | -4.54% |
Net income | 354.00M | 52.59% |
Net profit margin | 23.26 | 35.47% |
Earnings per share | 1.60 | 45.45% |
EBITDA | 540.00M | 41.36% |
Effective tax rate | 25.16% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 517.00M | 77.66% |
Total assets | 8.19B | 20.70% |
Total liabilities | 2.51B | 19.96% |
Total equity | 5.68B | — |
Shares outstanding | 221.19M | — |
Price to book | 0.99 | — |
Return on assets | 14.27% | — |
Return on capital | 17.99% | — |
Cash Flow
Net change in cash
| (DKK) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 354.00M | 52.59% |
Cash from operations | 389.00M | 37.46% |
Cash from investing | -59.00M | 65.70% |
Cash from financing | -399.00M | -34.80% |
Net change in cash | -72.00M | 60.66% |
Free cash flow | 256.12M | 39.10% |
About
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe. Wikipedia
Founded
1923
Website
Employees
2,736
